Clinical trials: Nocturia
Nocturia
Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
This is a multi-center, double-blind, placebo-controlled study with two weeks of daily oral administration of one of three dose levels of Paxerol or placebo in subjects with nocturia.
- Trial name
- NCT02646826
- Testing
- Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Wellesley Pharmaceuticals, LLC
Nocturia
Treatment of Patients With Nocturia (Non-PK Study)
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937378
- Testing
- SER120
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4
To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
- Trial name
- DB4 (NCT01900704)
- Testing
- SER120 750 ng, SER120 1500 ng
- Where
- United States
- Volunteers
- 810 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in…
- Trial name
- NCT03201419
- Testing
- FE 201836, Desmopressin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 302 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Obstructive Sleep Apnea, Nocturia
Mandibular Advancement Device and Changes in Nocturia
The main purpose of this study is to test is mandibular advancement device (MAD) use is associated with reductions in nocturia.
- Conditions
- Obstructive Sleep Apnea, Nocturia, OSA
- Trial name
- MAD (NCT05562388)
- Testing
- Somnodent Classic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Isabel Moreno Hay
Overactive Bladder, Parkinson Disease
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
The impact of urinary symptoms in Parkinson disease (PD) extends beyond worsened well-being. Urinary symptoms common in PD, especially incontinence and nocturia, are major risk factors for falls likely due to the combination of…
- Trial name
- BOSS PD (NCT03149809)
- Testing
- solifenacin, Pelvic floor muscle exercise-based behavioral therapy
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- VA Office of Research and Development
Urinary Incontinence
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets.
- Trial name
- NCT00323635
- Testing
- tolterodine
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Sleep Fragmentation, Poor Quality Sleep
Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production
Nocturia is prevalent in older adults and it vastly reduces quality of life. Yet its treatment remains inadequate because its causes are not well understood, especially nocturnal polyuria or increased urine production at night.
- Conditions
- Sleep Fragmentation, Poor Quality Sleep, Nocturia, Nocturnal Enuresis
- Trial name
- NCT03883724
- Testing
- Brief behavioral treatment of insomnia (BBTI), Information-only control (IC)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Nocturia
Long Term Safety Assessment of SER120 in Patients With Nocturia
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
- Trial name
- NCT00981682
- Testing
- SER120
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Urinary Incontinence
This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user satisfaction with the PureWick® Male External Catheter in a home setting.
- Trial name
- PUREST-M (NCT06850259)
- Testing
- PureWick® Urine Collection System, UltraFlex™ Self-Adhering Male External Catheter
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- C. R. Bard
Interstitial Cystitis, Chronic Interstitial Cystitis
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to gather information from the investigation of a non-pharmacological (non-drug) treatment known as low frequency pulsed electromagnetic field (PEMF).
- Conditions
- Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT04540887
- Testing
- Pulsed Electromagnetic Field (PEMF) Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Nocturia
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
- Trial name
- NCT01259128
- Testing
- SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Insomnia Disorder, Nocturia
A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia
A study to find out if daridorexant is safe and efficacious in patients with insomnia and comorbid nocturia
- Trial name
- NCT05597020
- Testing
- Daridorexant
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.